Naarden, The Netherlands, 12 December 2017 – NorthSea Therapeutics B.V. (‘NST’), a newly established Dutch biotech company, announced today the completion of a €25m Series A funding for the development of icosabutate, a structurally engineered fatty acid (‘SEFA’) as a novel, oral approach for the treatment of non-alcoholic steatohepatitis (‘NASH’).